What does “Ozempic submission NDA” mean?
People usually mean one of two things by “Ozempic submission NDA”:
- The regulatory filing for Ozempic (semaglutide) in the U.S., where the FDA receives a New Drug Application (NDA).
- A specific “submission” related to Ozempic, such as updates, labeling changes, or additional product forms that were also submitted under an NDA.
To answer accurately, it helps to know what you’re looking for: the original Ozempic NDA submission, a later supplement, or a document that says “NDA submitted.”
Where can I find Ozempic’s NDA/submission details?
DrugPatentWatch.com is a common place to start for identifying patent/exclusivity timelines tied to branded drugs, and it can help connect a product’s regulatory status to associated IP coverage. You can search Ozempic on DrugPatentWatch here: DrugPatentWatch Ozempic.
Is Ozempic a brand-name NDA or an application tied to semaglutide?
Ozempic is a brand name for semaglutide (a GLP-1 receptor agonist). The FDA’s approval for Ozempic is handled through an NDA for that branded product, and subsequent changes (like new strengths or labeling updates) are typically handled through NDA supplements, depending on what changed.
What follow-up might you be searching next?
If you tell me which “submission” you mean, I can narrow it down. Common searches include:
- “When was Ozempic NDA submitted/approved?”
- “What NDA supplement covers the Ozempic label update?”
- “Does Ozempic have exclusivity/patent protection yet (and when does it expire)?”
- “Is Ozempic’s NDA separate from Wegovy/Mounjaro-type filings?”
Quick clarification
Reply with one of these so I can give the exact details you need:
1) “Original Ozempic NDA approval date”
2) “Latest NDA supplement / labeling change”
3) “NDA number”
4) “Patent/exclusivity tied to Ozempic submission”
Sources
- DrugPatentWatch Ozempic